Encorafenib

Common brands: Braftovi, Mektovi, Erbitux, Opdivo, Pain Relief

Top reporter: Array Biopharma Inc.

Epidermal Growth Factor Receptor Antagonist [EPC]Corticosteroid [EPC]Programmed Death Receptor-1 Blocking Antibody [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Benzodiazepine [EPC]
9,531
Total Reports
6,524
Serious Reports
1,580
Death Reports
30
Reported Reactions
Death Report Ratio: High (16.58%)

Patient Demographics

Male
3,559
Female
3,485

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Encorafenib.

# Reaction Reports % of Total
1 DEATH 1,133
10.0%
2 OFF LABEL USE 1,122
9.9%
3 NAUSEA 826
7.3%
4 FATIGUE 746
6.6%
5 DIARRHOEA 616
5.4%
6 PYREXIA 583
5.2%
7 NEOPLASM PROGRESSION 552
4.9%
8 PRODUCT USE IN UNAPPROVED INDICATION 520
4.6%
9 VOMITING 467
4.1%
10 RASH 455
4.0%
11 SEROUS RETINAL DETACHMENT 334
3.0%
12 ARTHRALGIA 306
2.7%
13 DECREASED APPETITE 295
2.6%
14 MALAISE 286
2.5%
15 ASTHENIA 239
2.1%
16 DISEASE PROGRESSION 230
2.0%
17 MALIGNANT NEOPLASM PROGRESSION 225
2.0%
18 PAIN 221
2.0%
19 ACUTE KIDNEY INJURY 218
1.9%
20 VISION BLURRED 218
1.9%
21 CONSTIPATION 212
1.9%
22 HEADACHE 193
1.7%
23 VISUAL IMPAIRMENT 189
1.7%
24 ABDOMINAL PAIN 185
1.6%
25 ANAEMIA 177
1.6%
26 PRURITUS 164
1.5%
27 MYALGIA 158
1.4%
28 DYSPNOEA 154
1.4%
29 DEHYDRATION 144
1.3%
30 COLITIS 136
1.2%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.